Notice Number: NOT-HL-18-640

Key Dates
Release Date: July 11, 2018

Issued by
National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The purpose of this Notice is to inform potential applicants that the National Heart, Lung, and Blood Institute (NHLBI) will participate, effective immediately, in PA-18-723 "Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health (R01 Clinical Trial Optional)" issued by the National Institutes of Health.

The following changes and updates are made to PA-18-723 (shown in italics) to reflect NHLBI participation in this FOA.

Office of Behavioral and Social Sciences Research (OBSSR)
National Cancer Institute (NCI)
National Institute on Aging (NIA)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute on Drug Abuse (NIDA)
National Institute of Mental Health (NIMH)
National Institute of Nursing Research (NINR)
National Institute on Minority Health and Health Disparities (NIMHD)
National Center for Complementary and Integrative Health (NCCIH)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
National Heart, Lung, and Blood Institute (NHLBI)

Catalog of Federal Domestic Assistance (CFDA) Number(s)
93.242, 93.361, 93.213, 93.273, 93.393, 93.866, 93.855, 93.279, 93.307, 93.286, 93.837, 93.838, 93.839, 93.840, 93.233

Section I. Funding Opportunity Description

Research Objectives

The National Heart, Lung and Blood Institute (NHLBI) is interested in supporting research across the translational spectrum for the development and evaluation of interventions targeting adherence to behavioral or pharmacologic regimens for the prevention and management of heart, lung, blood, and sleep conditions in order reduce risk of disease or reduce morbidity and mortality. NHLBI is particularly interested in applications that a) focus on adherence as a strategy for reducing health disparities, b) integrate an understanding of the multi-level determinants of adherence and social and economic contextual factors, c) incorporate advances in behavioral science, mobile and connected health technology, and healthcare informatics, and/or d) focus on identifying and overcoming the barriers and facilitators for adherence to evidence-based guidelines by patients and practitioners.

Additional examples of interest to NHLBI:

• Studies investigating social determinants of health that contribute to disparities in adherence and health outcomes for heart, lung, blood, and sleep conditions.

• Investigations to understand the role of patient/provider communication in influencing medication adherence during transitions between health care settings

• An investigation of behavioral economic approaches to optimize adherence to a physical activity regimen among patients with cardiometabolic risk factors or disease.

• An investigation of factors that contribute to the persistence of adherence to physical activity recommendations across the lifespan.

• Studies to improve adherence in the implementation of evidence-based guidelines by practitioners, patients, and/or organizations across diverse populations and settings for heart, lung, blood, and sleep conditions.

• Research on the implementation barriers and facilitators for adherence and the use of innovative technologies for adherence to evidence-based guidelines for heart, lung, blood, and sleep health.

• Research that improves health equity by improving adherence to implementation of evidence-based guidelines across underrepresented populations.

Section VII. Agency Contacts

Scientific/Research Contact(s)

Nicole Redmond, MD, PhD, MPH
National Heart Lung and Blood Institute (NHLBI)
Telephone: 301-435-0379
Email: [email protected]

Financial/Grants Management Contact(s):

Christina Rinaldi
National Heart Lung and Blood Institute
Telephone: 301-827-8287
Email: [email protected]

All other aspects of this FOA remain the same

Inquiries

Please direct all inquiries to:

Nicole Redmond, MD, PhD, MPH
Division of Cardiovascular Sciences (DCVS)
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0379
Email: [email protected]